0000899243-22-028506.txt : 20220812 0000899243-22-028506.hdr.sgml : 20220812 20220812164938 ACCESSION NUMBER: 0000899243-22-028506 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220811 FILED AS OF DATE: 20220812 DATE AS OF CHANGE: 20220812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KURIYEL RALF CENTRAL INDEX KEY: 0001733143 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 221160888 MAIL ADDRESS: STREET 1: 41 SEYON ST STREET 2: BLDG 1, STE. 100 CITY: WALTHAM STATE: MA ZIP: 02452 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-11 0 0000730272 REPLIGEN CORP RGEN 0001733143 KURIYEL RALF C/O REPLIGEN CORPORATION 41 SEYON ST., BLDG 1, STE 100 WALTHAM MA 02453 0 1 0 0 Senior VP, R&D Common Stock 2022-08-11 4 M 0 2000 33.05 A 22110 D Common Stock 2022-08-11 4 M 0 1354 59.52 A 23464 D Common Stock 2022-08-11 4 M 0 646 86.10 A 24110 D Common Stock 2022-08-11 4 S 0 800 255.20 D 23310 D Common Stock 2022-08-11 4 S 0 4040 254.14 D 19270 D Stock Option (Right to Buy) 33.05 2022-08-11 4 M 0 2000 0.00 A 2026-12-14 Common Stock 2000 0 D Stock Option (Right to Buy) 59.52 2022-08-11 4 M 0 1354 0.00 A 2029-02-28 Common Stock 1354 0 D Stock Option (Right to Buy) 86.10 2022-08-11 4 M 0 646 0.00 A 2027-02-23 Common Stock 646 400 D $254.14 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.10 to $254.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option is fully vested and exercisable. 1,046 shares vest and become exercisable on 2/27/2023. /s/ Kimberly Brown (Attorney in Fact) 2022-08-12